How autoinjector primary packaging works, from barrel to seal

Quick answer: An autoinjector is a spring-driven housing built around a primary container, almost always a prefilled syringe (PFS) or small cartridge. The packaging decisions that matter are made at that inner container: glass or polymer barrel, staked or insert needle, siliconized or silicone-free. None of those choices is universally “better”; each trades breakage resistance, extractables, dose accuracy and cost against each other, and the right pick depends on the molecule, the fill volume and data your own regulatory and quality teams accept.

A daily autoinjector approval is really a packaging milestone

UCB’s zilucoplan (Zilbrysq) just picked up a second delivery option. Zilucoplan has been available since 2023 as a self-administered prefilled syringe for adults with gMG, and the new autoinjector is designed to automatically deliver a pre-defined dose when pressed against the skin, giving patients and caregivers a second, portable option for daily dosing. Commercial launch is expected in the first quarter of 2027, with three strengths of 16.6 mg, 23 mg, and 32.4 mg supplied in 28-day cartons.

The clinical and usability numbers behind the filing are the kind of data any team moving a molecule from PFS to autoinjector has to generate. A phase 3b study enrolled 31 patients with gMG who self-administered the drug once daily with the autoinjector, and complete dose delivery was achieved for 99.8% of autoinjectors used and returned. A separate human factor validation study found that 90% of participants successfully completed an injection with the autoinjector on their first attempt without training. Tolerability was mixed in with the usability data too, since device switches can surface new handling issues even when the drug itself is unchanged.

Zilbrysq autoinjector usability and safety data
Zilbrysq autoinjector usability and safety data

None of that is unusual. Any sponsor converting a PFS-only product into an autoinjector has to show the device delivers the same dose, that patients can use it correctly, and that the container inside still protects the drug. That inner container is where the packaging engineering actually happens.

What’s actually inside an autoinjector

Strip the plastic housing off a typical disposable autoinjector and you find a spring, a trigger mechanism, a needle shield and, at the centre, a prefilled syringe barrel with a plunger stopper and a fixed or insert needle. The device supplies the force and the safety features; the syringe is still the primary container that has to pass the same container closure, stability and extractables programme as a standalone PFS. ISO 11040 includes a part covering injection systems such as autoinjectors and other automated delivery devices that employ a prefilled syringe, built on top of the parts that cover the syringe components themselves.

That matters for packaging teams because an autoinjector project rarely starts from a blank sheet. It usually starts from an existing PFS configuration and asks whether that barrel, stopper and needle combination can survive the spring-driven insertion force, the device’s own storage orientation and any new cold chain handling the device introduces. The barrel material decision made years earlier, often for a standalone syringe, carries straight through.

Glass or polymer: the barrel material trade-off

Even though glass syringes are predominantly used for primary containment of parenterals, the pharmaceutical industry continues to deal with certain limitations associated with glass prefilled systems. That is especially true when the drug is administered through autoinjectors or pens, where glass cracks and breakage can be a serious risk for patients. Polymer barrels, mostly cyclic olefin polymer (COP) or cyclic olefin copolymer (COC), were developed as an alternative. Next-generation polymer syringes from the COP family offer break resistance, dosage precision and reduced extractables and leachables, benefits that are gaining attention from manufacturers looking for new answers to drug delivery and administration challenges.

One commercial COP system is marketed specifically on removing two long-standing PFS headaches. Its insert-needle syringe design protects sensitive molecules because no silicone oil is used for plunger functionality, and the barrel is free of tungsten and glue. On the COC side, cyclic olefin copolymer is one of the glass alternatives used in certain applications such as emergency medicine, with Topas Advanced Polymers pushing to establish COC as a material of choice for prefilled syringes and vials.

The table below is a starting point for a design conversation, not a verdict. Actual extractables profiles, breakage rates and functional performance depend on the specific grade, the forming process and how the barrel is paired with its stopper, needle and lubricant.

Attribute Borosilicate glass (Type I) COP barrel COC barrel
Breakage risk Present; a known concern in spring-driven autoinjectors Low; break-resistant by design Low; break-resistant by design
Needle fixing typically used Staked (tungsten pin-formed) or luer Insert-moulded or staked, grade-dependent Insert-moulded or staked, grade-dependent
Tungsten residue risk Possible from pin-forming step unless specified tungsten-free Can be formulated tungsten-free Can be formulated tungsten-free
Silicone oil need Usually siliconized for plunger glide Some grades silicone-free with barrier-coated stoppers Resin itself needs lubrication; grade-dependent
Governing component standard ISO 11040-4; Ph. Eur./USP glass chapters ISO 11040-6; supplier DMF ISO 11040-6; supplier DMF

For a side-by-side of generic material properties beyond syringe barrels, the material properties reference is a useful starting table, though pharma-grade resins and glass still need supplier data sheets for anything you intend to submit.

Tungsten, silicone oil and the leachables they bring

Two manufacturing residues dominate the PFS compatibility literature. During the manufacture of most glass syringe barrels, a tungsten probe is used to form the fluid path in the tip of the syringe, potentially leaving residual tungsten oxide vapor and tungsten particles. Aggregation of biologic products resulting from incompatibility of tungsten residue and silicone oil is widely regarded as the greatest container compatibility risk when using a prefilled syringe.

The effect is measurable at low concentrations. Published research reports that concentrations of tungsten as low as 1 ppm in the drug product can produce measurable protein aggregation. A 2025 study went further: tungsten pin extracts induced markedly more aggregation, fragmentation and subvisible particle formation than commercial tungsten salts, a 14-fold increase in aggregates for one monoclonal antibody at 100 ppm. That said, routine supply isn’t necessarily a problem: analysis of 500 syringes from various manufacturers indicated that leached tungsten is generally well below the level associated with measurable aggregation. Supplier washing and forming process control is what keeps it there.

Silicone oil carries its own leachables risk, separate from tungsten. Industry presentations on parenteral extractables and leachables note plainly that silicone oil leachables cause product aggregation, which is why silicone-free or cross-linked silicone options exist for sensitive biologics, at the cost of needing a different lubrication strategy for the plunger.

The standards that define the components

ISO 11040 is the reference series for prefilled syringe hardware. Part 4 covers glass barrels for injectables and sterilised subassembled syringes ready for filling, while Part 6 covers polymer barrels for injectables and sterilised subassembled syringes. Part 7 covers packaging for pre-sterilized fill and finish applications, and Part 8 specifies requirements and test methods for the finished prefilled syringe as a complete device. The 2024 edition of Part 4 also extended its scope: that document also specifies components that are part of the sterilised subassembled syringe ready for filling, covering needle, syringe closure system and closure tightness requirements in detail.

Alongside ISO 11040, the applicable pharmacopoeia (USP, Ph. Eur. or JP) sets compendial requirements for the elastomeric and plastic components themselves, separate from the finished-device standard. None of this is optional reading if you’re specifying a new barrel: a supplier’s data sheet claiming “USP Class VI” or an ISO 11040 part number tells you a test was passed, not that the combination is right for your molecule. That determination sits with your own regulatory and quality teams, working from the applicable pharmacopoeia and your own stability and compatibility data.

Proving the seal holds: container closure integrity testing

Breakage and leachables are one risk category. A compromised seal is another, and it is tested separately. Container closure integrity testing confirms a sealed package maintains its sterile barrier throughout shelf life; failures can compromise sterility and trigger recalls. USP General Chapter 1207 splits leak-test methods into deterministic methods, which are direct physical measurements, and probabilistic methods, which rely on statistical inference, and the chapter prefers deterministic methods where the product-package system allows it.

That preference has reshaped which tests labs run. The release of USP <1207> prompted guidance suggesting dye immersion tests be avoided in favour of high-voltage leak detection (HVLD) or vacuum decay testing, which give more reproducible, quantitative results. Sensitivity varies a lot between methods: vacuum decay can reliably detect defects as small as 5 micrometres, while helium leak detection is far more sensitive, able to detect defects down to below 0.01 micrometres. For a specific PFS acceptance criterion, published research used the US Pharmacopeia’s threshold of 6×10⁻⁶ mbar·L/s as the cut-off below which a PFS is considered tight, with that figure drawn directly from USP <1207>.

Method USP <1207> category Destructive? Typical fit
Vacuum decay Deterministic No Liquid and lyophilized products; gross-to-moderate leak detection
Helium leak detection Deterministic Usually yes Highest sensitivity; sub-micron defects, cryogenic storage checks
High-voltage leak detection (HVLD) Deterministic No Liquid-filled containers; in-line or at-line use
Dye ingress Probabilistic Yes Legacy method; being phased out in favour of deterministic tests

Working across micrometre and mbar·L/s units day to day gets tedious; the unit converter handles the gsm, micron and related conversions that come up when comparing supplier data sheets written in different unit systems.

Extractables and leachables: what the testing actually proves

E&L testing answers a narrower question than CCI testing: not “does the seal leak” but “what does the container give up into the drug, and does it matter.” Manufacturers assessing a prefilled syringe need to consider the materials used for the barrel, plunger, tip cap or needle shield, the needle itself and any adhesives or lubricants such as silicone oil, and because so many of these materials sit in direct contact with the drug product, PFS systems often need a more involved E&L analysis than a simple vial.

The field’s working framework comes from PQRI’s Parenteral and Ophthalmic Drug Products working group. Its recommended process starts with demonstrating that materials of construction meet relevant compendial monographs and chapters or ISO standards, then runs an extraction study to identify and, as appropriate, quantify all relevant extractables. A migration study then measures the levels of leachables in the actual drug product under conditions of use, followed by a toxicological assessment of what was found. That sequence, not a single pass/fail test, is what a dossier needs to show.

Questions to ask your suppliers and your regulatory and quality teams

  • For a glass barrel: is it formed with a tungsten pin, and what residual tungsten level does the supplier’s certificate of analysis report, in ppm?
  • For a polymer barrel: which resin family (COP or COC), which grade, and what extractables data package already exists for that grade in a syringe format?
  • Is the barrel siliconized, cross-linked silicone, or silicone-free, and what lubrication does the stopper or plunger use instead if silicone-free?
  • Which ISO 11040 parts does the component or finished syringe assembly comply with, and is that documented against the current edition?
  • Which CCI method was used to validate the closure system, deterministic or probabilistic, and at what detection limit?
  • Has an E&L study been run under PQRI-aligned principles for this specific barrel, stopper and needle combination, not just for the resin or glass in isolation?
  • If the device is an autoinjector, has the spring-driven insertion force and storage orientation been checked against the syringe’s own mechanical specification?

None of these questions has a single right answer across every drug product. Your regulatory affairs and quality teams, working against the applicable pharmacopoeia and your specific molecule’s stability data, are the ones who turn supplier answers into a packaging decision. A printable version of a supplier qualification checklist along similar lines is on the site’s downloads page.

What this means for you

If you’re moving a product from vial to PFS, or from PFS to autoinjector, start the barrel material conversation early and treat it as a data exercise, not a commodity purchase. Ask for tungsten and silicone data in writing, not just a material family name. Decide your CCI test method based on your product’s sensitivity to the test itself, not just on what a lab already has running. And keep E&L testing scoped to the actual component stack going into the device, since a resin’s generic extractables profile is a starting point, not a substitute for testing your own configuration. Final material selection and any compliance claim stay with your own regulatory and quality functions and the pharmacopoeia or authority that governs your market.

Sources

This article is general education about packaging materials, formats and test methods. It is not regulatory, quality or medical advice. For a real product, confirm material choice, testing and compliance with your regulatory and quality teams and the applicable pharmacopoeia and authority.